A Comparative Single Dose Pharmacokinetic and Safety Study of 4 mg or 8 mg Ramelteon in Adolescents With Insomnia Characterized by Difficulty With Sleep Onset, Children With Insomnia Associated With ADHD, and Healthy Adults.
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2013
At a glance
- Drugs Ramelteon (Primary)
- Indications Insomnia
- Focus Pharmacokinetics
- 26 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Nov 2010 Official Title amended as reported by ClinicalTrials.gov.
- 29 Nov 2010 Planned End Date changed from 1 Apr 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.